0 14 Identification identification NN 15 18 and and CC 19 35 characterization characterization NN 36 38 of of IN 39 40 a a DT 41 59 leukocyte-specific leukocyte-specific JJ 60 69 component component NN 70 72 of of IN 73 76 the the DT 77 84 nuclear nuclear JJ 85 89 body body NN 89 90 . . . 92 95 The the DT 96 103 nuclear nuclear JJ 104 108 body body NN 109 110 ( ( ( 110 112 NB NB NNP 112 113 ) ) ) 114 116 is be VBZ 117 118 a a DT 119 127 cellular cellular JJ 128 137 organelle organelle NN 138 142 that that WDT 143 145 is be VBZ 146 154 involved involve VBN 155 157 in in IN 158 161 the the DT 162 174 pathogenesis pathogenesis NN 175 177 of of IN 178 183 acute acute JJ 184 197 promyelocytic promyelocytic JJ 198 206 leukemia leukemia NN 207 210 and and CC 211 216 viral viral JJ 217 226 infection infection NN 226 227 . . . 228 231 The the DT 232 234 NB NB NNP 235 237 is be VBZ 238 242 also also RB 243 244 a a DT 245 251 target target NN 252 254 of of IN 255 265 antibodies antibody NNS 266 268 in in IN 269 272 the the DT 273 278 serum serum NN 279 281 of of IN 282 290 patients patient NNS 291 295 with with IN 296 299 the the DT 300 310 autoimmune autoimmune JJ 311 318 disease disease NN 319 326 primary primary JJ 327 334 biliary biliary JJ 335 344 cirrhosis cirrhosis NN 344 345 . . . 346 348 In in IN 349 353 this this DT 354 359 study study NN 359 360 , , , 361 366 serum serum NN 367 371 from from IN 372 373 a a DT 374 381 patient patient NN 382 386 with with IN 387 394 primary primary JJ 395 402 biliary biliary JJ 403 412 cirrhosis cirrhosis NN 413 416 was be VBD 417 421 used use VBN 422 424 to to TO 425 433 identify identify VB 434 435 a a DT 436 440 cDNA cdna NN 441 449 encoding encode VBG 450 451 a a DT 452 457 novel novel JJ 458 467 component component NN 468 470 of of IN 471 474 the the DT 475 477 NB NB NNP 477 478 , , , 479 480 a a DT 481 488 140-kDa 140-kda JJ 489 496 protein protein NN 497 507 designated designate VBN 508 513 Sp140 Sp140 NNP 513 514 . . . 515 518 The the DT 519 528 predicted predict VBN 529 534 amino amino NN 535 539 acid acid NN 540 548 sequence sequence NN 549 551 of of IN 552 555 the the DT 556 570 amino-terminal amino-terminal JJ 571 578 portion portion NN 579 581 of of IN 582 587 Sp140 Sp140 NNP 588 591 was be VBD 592 599 similar similar JJ 600 602 to to TO 603 608 Sp100 Sp100 NNP 608 609 , , , 610 611 a a DT 612 622 previously previously RB 623 633 identified identify VBN 634 636 NB NB NNP 637 644 protein protein NN 644 645 . . . 646 649 The the DT 650 658 carboxyl carboxyl NN 659 666 portion portion NN 667 669 of of IN 670 675 Sp140 Sp140 NNP 676 685 contained contain VBD 686 687 a a DT 688 699 zinc-finger zinc-finger NN 700 706 domain domain NN 707 710 and and CC 711 712 a a DT 713 724 bromodomain bromodomain NN 724 725 , , , 726 732 motifs motif NNS 733 737 that that WDT 738 741 are be VBP 742 749 present present JJ 750 752 in in IN 753 761 proteins protein NNS 762 772 regulating regulate VBG 773 777 gene gene NN 778 791 transcription transcription NN 791 792 . . . 793 797 High high JJ 798 804 levels level NNS 805 807 of of IN 808 813 Sp140 Sp140 NNP 814 818 mRNA mRNA NNP 819 823 were be VBD 824 832 detected detect VBN 833 835 in in IN 836 841 human human JJ 842 848 spleen spleen NN 849 852 and and CC 853 863 peripheral peripheral JJ 864 869 blood blood NN 870 880 leukocytes leukocyte NNS 880 881 , , , 882 885 but but CC 886 889 not not RB 890 895 other other JJ 896 901 human human JJ 902 909 tissues tissue NNS 909 910 . . . 911 914 The the DT 915 920 level level NN 921 923 of of IN 924 929 SP140 SP140 NNP 930 934 mRNA mRNA NNP 935 937 in in IN 938 945 myeloid myeloid JJ 946 955 precursor precursor NN 956 960 cell cell NN 961 966 lines line NNS 967 971 HL60 HL60 NNP 972 975 and and CC 976 979 NB4 NB4 NNP 980 988 markedly markedly RB 989 998 increased increase VBD 999 1001 in in IN 1002 1010 response response NN 1011 1013 to to TO 1014 1024 chemically chemically RB 1025 1032 induced induce VBN 1033 1041 cellular cellular JJ 1042 1057 differentiation differentiation NN 1057 1058 . . . 1059 1078 Immunohistochemical immunohistochemical JJ 1079 1089 techniques technique NNS 1090 1094 were be VBD 1095 1099 used use VBN 1100 1102 to to TO 1103 1114 demonstrate demonstrate VB 1115 1119 that that IN 1120 1125 SP140 sp140 NN 1126 1135 localized localize VBD 1136 1138 to to TO 1139 1142 the the DT 1143 1145 NB nb NN 1146 1148 in in IN 1149 1163 differentiated differentiate VBN 1164 1168 HL60 hl60 NN 1169 1172 and and CC 1173 1176 NB4 nb4 NN 1177 1182 cells cell NNS 1182 1183 . . . 1184 1187 The the DT 1188 1196 location location NN 1197 1199 of of IN 1200 1205 Sp140 sp140 NN 1206 1208 in in IN 1209 1212 the the DT 1213 1215 NB NB NNP 1215 1216 , , , 1217 1220 and and CC 1221 1231 expression expression NN 1232 1234 of of IN 1235 1239 this this DT 1240 1244 gene gene NN 1245 1247 in in IN 1248 1253 cells cell NNS 1254 1262 involved involve VBN 1263 1265 in in IN 1266 1270 host host NN 1271 1278 defense defense NN 1278 1279 , , , 1280 1287 suggest suggest VBP 1288 1292 that that IN 1293 1298 Sp140 sp140 NN 1299 1302 may may MD 1303 1305 be be VB 1306 1314 involved involve VBN 1315 1317 in in IN 1318 1321 the the DT 1322 1334 pathogenesis pathogenesis NN 1335 1337 of of IN 1338 1343 acute acute JJ 1344 1357 promyelocytic promyelocytic JJ 1358 1366 leukemia leukemia NN 1367 1370 and and CC 1371 1376 viral viral JJ 1377 1386 infection infection NN 1386 1387 . . .